BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 28524247)

  • 1. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
    Matsuo K; Shimada M; Aoki Y; Sakamoto M; Takeshima N; Fujiwara H; Matsumoto T; Mikami M; Sugiyama T
    Int J Cancer; 2017 Sep; 141(5):1042-1051. PubMed ID: 28524247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
    Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
    Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of treatment-related complications in women with clinical stage IB-IIB cervical cancer: A nationwide cohort study in Japan.
    Machida H; Matsuo K; Furusawa A; Kita T; Kitagawa R; Mikami M
    PLoS One; 2019; 14(1):e0210125. PubMed ID: 30615679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for recurrence in patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation.
    Lin HH; Cheng WF; Chan KW; Chang DY; Chen CK; Huang SC
    Obstet Gynecol; 1996 Aug; 88(2):274-9. PubMed ID: 8692515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone.
    Matsuo K; Nusbaum DJ; Machida H; Huang Y; Khetan V; Matsuzaki S; Klar M; Grubbs BH; Roman LD; Wright JD
    Am J Obstet Gynecol; 2020 May; 222(5):484.e1-484.e15. PubMed ID: 31678092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].
    Wang W; Shang C; Huang J; Chen S; Shen H; Yao S
    Zhonghua Fu Chan Ke Za Zhi; 2015 Dec; 50(12):894-901. PubMed ID: 26887872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy.
    Tsai CS; Lai CH; Wang CC; Chang JT; Chang TC; Tseng CJ; Hong JH
    Gynecol Oncol; 1999 Dec; 75(3):328-33. PubMed ID: 10600284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy.
    Liu MT; Hsu JC; Liu WS; Wang AY; Huang WT; Chang TH; Pi CP; Huang CY; Huang CC; Chou PH; Chen TH
    Eur J Cancer Care (Engl); 2008 Mar; 17(2):174-81. PubMed ID: 18302655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer.
    Matsuo K; Shimada M; Nakamura K; Takei Y; Ushijima K; Sumi T; Ohara T; Yahata H; Mikami M; Sugiyama T
    Eur J Surg Oncol; 2019 Aug; 45(8):1417-1424. PubMed ID: 30846298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer.
    Matsuo K; Shimada M; Saito T; Takehara K; Tokunaga H; Watanabe Y; Todo Y; Morishige KI; Mikami M; Sugiyama T
    J Gynecol Oncol; 2018 Jan; 29(1):e11. PubMed ID: 29185269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early stage cervical cancer with negative pelvic lymph nodes: pattern of failure and complication following radical hysterectomy and adjuvant radiotherapy.
    Chen SW; Liang JA; Yang SN; Lin FJ
    Eur J Gynaecol Oncol; 2004; 25(1):81-6. PubMed ID: 15053068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical cancer: combined modality therapy.
    Grigsby PW
    Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Prognostic Factors Affecting the Outcome of Stage IB-IIB Cervical Cancer Treated by Radical Hysterectomy and Pelvic Lymphadenectomy.
    Xia X; Xu H; Wang Z; Liu R; Hu T; Li S
    Am J Clin Oncol; 2016 Dec; 39(6):604-608. PubMed ID: 24937635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
    Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
    Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting.
    Jung PS; Kim DY; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    PLoS One; 2015; 10(7):e0132298. PubMed ID: 26176626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases.
    Lai CH; Hong JH; Hsueh S; Ng KK; Chang TC; Tseng CJ; Chou HH; Huang KG
    Cancer; 1999 Apr; 85(7):1537-46. PubMed ID: 10193944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].
    Wen HW; Huang WP; Liu TY; Ma K; Tao X; Zhu LR; Liao QP
    Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):920-4. PubMed ID: 24495686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.